Rivaroxaban
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Medical University of GdanskSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eb-Select Single-Target Car-Nk Cells Essen Biotech | Phase 1/2 | CC |
Fludarabine Essen Biotech | Phase 1/2 | CC |
Cyclophosphamide Essen Biotech | Phase 1/2 | CC |
Dual-Target Antigen-Selected Car-Nk Essen Biotech | Phase 1/2 | CC |
S 64315 Novartis Pharmaceuticals | Phase 1 | CC |
Apixaban Medical University of Gdansk | N/A | D |
Enoxaparin Medical University of Gdansk | N/A | D |
Same molecule, other indications
Rivaroxaban is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →